Curis, Inc. (CRIS) Sets 52 Week Low; Strong Momentum for Sellers

January 18, 2018 - By Michael Collier

Investors sentiment decreased to 1.48 in Q3 2017. Its down 0.04, from 1.52 in 2017Q2. It dropped, as 14 investors sold Curis, Inc. shares while 15 reduced holdings. 13 funds opened positions while 30 raised stakes. 76.32 million shares or 4.90% more from 72.75 million shares in 2017Q2 were reported.
Vident Advisory invested in 0.05% or 656,529 shares. Jpmorgan Chase & has invested 0% in Curis, Inc. (NASDAQ:CRIS). 1.15M were reported by Cormorant Asset Mgmt Ltd Liability Corporation. 2.59M were accumulated by Polar Cap Llp. 43,833 are owned by Sg Americas Limited Liability Corp. Millennium Mgmt Lc invested in 0% or 218,429 shares. 48,500 were accumulated by Strs Ohio. Voya Invest Limited Liability Corp owns 68,138 shares. Ameritas Inv Prns stated it has 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). First Republic Investment Mgmt holds 12,950 shares or 0% of its portfolio. Raymond James Fincl holds 10,760 shares or 0% of its portfolio. Fmr Ltd Liability accumulated 14.17 million shares or 0% of the stock. Nationwide Fund Advisors invested 0% in Curis, Inc. (NASDAQ:CRIS). Deutsche Natl Bank Ag holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 475,902 shares. 8,444 are held by Barclays Public Ltd.

The stock of Curis, Inc. (NASDAQ:CRIS) hit a new 52-week low and has $0.64 target or 9.00 % below today’s $0.70 share price. The 7 months bearish chart indicates high risk for the $114.77M company. The 1-year low was reported on Jan, 18 by Barchart.com. If the $0.64 price target is reached, the company will be worth $10.33 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 2.79% or $0.0201 during the last trading session, reaching $0.6999. About 1.48 million shares traded. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since January 18, 2017 and is uptrending. It has underperformed by 14.23% the S&P500.

Analysts await Curis, Inc. (NASDAQ:CRIS) to report earnings on March, 8. They expect $-0.09 EPS, down 12.50 % or $0.01 from last year’s $-0.08 per share. After $-0.11 actual EPS reported by Curis, Inc. for the previous quarter, Wall Street now forecasts -18.18 % EPS growth.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Among 6 analysts covering Curis (NASDAQ:CRIS), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Curis had 8 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 23 by Guggenheim. The company was initiated on Tuesday, August 11 by FBR Capital. The stock of Curis, Inc. (NASDAQ:CRIS) has “Buy” rating given on Monday, November 9 by TH Capital. Roth Capital maintained the shares of CRIS in report on Monday, November 9 with “Buy” rating. Zacks downgraded Curis, Inc. (NASDAQ:CRIS) on Monday, September 21 to “Sell” rating. The company was downgraded on Tuesday, September 1 by Zacks.

Another recent and important Curis, Inc. (NASDAQ:CRIS) news was published by Prnewswire.com which published an article titled: “Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule …” on January 17, 2018.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $114.77 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: